Renal Mechanism of SGLT2 Inhibition

This study examines how a class of diabetes drugs called SGLT2 inhibitors (such as empagliflozin or dapagliflozin) affect the kidneys in people with Type 2 diabetes. These medications are known to protect the kidneys, and this study wants to understand exactly how they work. **You may be eligible if...** - You are between 18 and 80 years old - You have had Type 2 diabetes for at least 3 years - Your kidney function (eGFR) is between 45 and 90 mL/min — meaning your kidneys are moderately affected but still functioning - You are not currently taking an SGLT2 inhibitor **You may NOT be eligible if...** - Your kidney function is severely impaired (eGFR below 45) - You have Type 1 diabetes - You have had a heart attack, stroke, or major cardiovascular event recently - You are pregnant or planning to become pregnant - You have contraindications to the study medications or tests Talk to your doctor to see if this trial is right for you.